COVID-19 vaccine A new type of Covid-19 vaccine just released its results. Cutting hospitalization in half among already vaccinated patients and successful no matter the variant
The stock is up +69% @89M$US market valuation in the after-hours on the NASDAQ. In 2020-2021, it was valued between 300-400M$US.
Let's track where the valuation of this stock will go over time as it could be indicative of what our vaccine could possibly be valued, in due time.
Trial Of New Covid Treatment Yields Encouraging Results: Study
A single-injection antiviral treatment for newly-infected Covid-19 patients reduced the risk of hospitalization by half in a large-scale clinical trial, according to a study published on Wednesday.
Stanford University professor Jeffrey Glenn, coauthor of the study published in the New England Journal of Medicine (NEJM), said the new drug "showed profound benefits for vaccinated and unvaccinated people alike."
While the number of Americans dying daily of coronavirus has fallen to around 500, treatments for the disease remain limited. One of the most common, Paxlovid made by Pfizer, involves taking 30 pills over five days.
The new treatment involves a single dose of pegylated lambda-interferon, a synthetic version of a naturally occurring protein that infected cells secrete to defend against viral infection.
"What it does is it binds receptors on the surfaces of cells that activate our own antiviral defense mechanisms," said Glenn, a professor of medicine, microbiology and immunology who heads the Stanford Biosecurity and Pandemic Preparedness Initiative.
https://www.barrons.com/amp/news/trial-of-new-covid-treatment-yields-encouraging-results-study-01675893908
https://www.nejm.org/doi/full/10.1056/NEJMoa2209760?query=featured_home
https://www.cnbc.com/quotes/EIGR